Last reviewed · How we verify
NCT06797037
Proof of Concept to Assess the Feasibility of a Decentralised Pathway Coordinated by the Advanced Practice Nurse for Patients Receiving Oral Treatment for Cancer or Malignant Haemopathy (ACCELER PLATFORM)
NA trial testing Decentralised Pathway Coordinated by the Advanced Practice Nurse in Solid Cancer in 33 participants. Currently enrolling.
19 May 2027
Quick facts
| Lead sponsor | Institut Claudius Regaud |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 33 |
| Start date | 19 May 2025 |
| Primary completion | 19 May 2027 |
| Estimated completion | 19 May 2027 |
| Sites | 1 location across France |
Drugs / interventions tested
- Decentralised Pathway Coordinated by the Advanced Practice Nurse
Conditions studied
- Solid Cancer — all drugs for Solid Cancer →
- Haematological Malignancies — all drugs for Haematological Malignancies →
Sponsor
Institut Claudius Regaud — full company profile →
Who can join
18 and older, any sex, with Solid Cancer or Haematological Malignancies. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open-label, single-centre, category 2 "Jardé Law" proof-of-concept study designed to demonstrate the feasibility of a decentralised care pathway for patients with cancer or haematological malignancies receiving oral treatment. The study will be conducted on a population of 33 patients. In current practice, patients with certain solid cancers or haematological malignancies may be prescribed oral chemotherapy on a retroceded basis. In these cases, the oncologist (coordinating investigator) sees the patient for a consultation every 3 cycles to prescribe/renew the treatment for approximately 3 months. Every month, the patient returns to the centre to have the treatment dispensed by the hospital pharmacy. No medical consultation is associated with this visit. In this study, it is proposed to decentralise the delivery of treatment to these patients by introducing two visits to the patient's home by a service-providing nurse. The decentralised patient pathway will be organised and monitored by the Advanced Practice Nurse (APN) at the investigating centre, who will be responsible in particular for coordination with the service-providing nurse and the hospital pharmacy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06797037
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Solid Cancer
Currently open trials in the same condition.
- NCT07242417 — TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors · EARLY_PHASE1 · recruiting
- NCT07281326 — A Study of AK138D1 in Advanced Malignant Tumors · Phase 1 · recruiting
- NCT06771622 — Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · active not recruiting
- NCT06730386 — A Phase I Study of AK138D1 in the Treatment of Advanced Solid Tumors · Phase 1 · recruiting
- NCT06763159 — A Study of HS-20124 in Patients with Advanced Solid Tumors · Phase 1 · recruiting
Other Institut Claudius Regaud trials
Trials by the same sponsor.
- NCT07427186 — Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy of Immunotherapy in Patients With Early Stage · NA · not yet recruiting
- NCT07233928 — Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Canc · NA · recruiting
- NCT06967961 — Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers · NA · recruiting
- NCT06408038 — Are CK+/CD45+ Double-Positive Circulating Cells of Tumor-origin? Characterization in METAstatic Breast Cancer · NA · completed
- NCT06371339 — Optimization With a Gamma Camera of the Individualized Patient Dosimetry in Radioiodine Therapy of Thyroid Diseases · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06797037 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institut Claudius Regaud
- Last refreshed: 20 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06797037.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing